- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date: KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Sep 4, 2018 P1b/2, N=329, Recruiting, Recruiting --> Completed | Trial completion date: Aug 2018 --> Jul 2017 | Trial primary completion date: Feb 2018 --> Jul 2017 N=191 --> 329 | Trial completion date: Feb 2020 --> May 2019 | Trial primary completion date: Aug 2019 --> May 2019
- |||||||||| Review, Journal: Emerging therapies in advanced hepatocellular carcinoma. (Pubmed Central) - Aug 9, 2018
Advanced HCC patients are difficult to treat with poor outcomes. After initial approval of sorafenib in 2007, we recently have multiple new agents that showed benefit and promising activity, and are set to change the landscape of HCC treatment.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Aug 8, 2018 P2, N=13, Not yet recruiting, After initial approval of sorafenib in 2007, we recently have multiple new agents that showed benefit and promising activity, and are set to change the landscape of HCC treatment. Initiation date: Jul 2018 --> Oct 2018
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date, Pan tumor, Metastases: Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling (clinicaltrials.gov) - Aug 2, 2018 P2, N=0, Withdrawn, N=30 --> 104 | Trial completion date: Feb 2019 --> Dec 2020 | Trial primary completion date: Aug 2018 --> Aug 2019 N=39 --> 0 | Trial completion date: Jun 2019 --> Jun 2021 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2018 --> Jun 2020 | Initiation date: Jun 2016 --> Jul 2018
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma (clinicaltrials.gov) - Jun 26, 2018 P2, N=33, Active, not recruiting, It is important to continue to report these side effects, and further studies are needed to elucidate potential risk factors for their development, as well as to determine prognosis after development. Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - May 1, 2018 P2, N=13, Not yet recruiting, Trial completion date: Jun 2018 --> Sep 2018 Initiation date: Mar 2018 --> Jul 2018
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Post-Marketing Surveillance of Lenvima in Korean Patients (clinicaltrials.gov) - Apr 27, 2018 P=N/A, N=3000, Recruiting, Initiation date: Mar 2018 --> Jul 2018 Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Jul 2021 --> Oct 2021
- |||||||||| Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Apr 4, 2018 P2, N=39, Recruiting, Not yet recruiting --> Recruiting Trial completion date: Jan 2018 --> Mar 2019 | Trial primary completion date: Jan 2018 --> Mar 2019
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker: Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) - Mar 29, 2018 P2, N=60, Recruiting, Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Sep 2022 | Trial primary completion date: Sep 2018 --> Sep 2020
|